Atara Biotherapeutics (ATRA) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

ATRA Stock Forecast

Atara Biotherapeutics stock forecast is as follows: an average price target of $10.33 (represents a -8.83% downside from ATRA’s last price of $11.33) and a rating consensus of 'Sell', based on 1 wall street analysts offering a 1-year stock forecast.

ATRA Price Target

The average price target for Atara Biotherapeutics (ATRA) is $10.33 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $18.00 to $3.00. This represents a potential -8.83% downside from ATRA's last price of $11.33.

ATRA Analyst Ratings

Sell

According to 1 Wall Street analysts, Atara Biotherapeutics's rating consensus is 'Sell'. The analyst rating breakdown for ATRA stock is 0 'Strong Buy' (0.00%), 0 'Buy' (0.00%), 0 'Hold' (0.00%), 1 'Sell' (100.00%), and 0 'Strong Sell' (0.00%).

Atara Biotherapeutics Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Nov 13, 2024	Benjamin Burnett	Stifel Nicolaus	$10.00	$7.58	31.93%	-11.74%
Aug 16, 2024	Salim Syed	Mizuho Securities	$18.00	$6.83	163.54%	58.87%
Aug 09, 2022	-	Goldman Sachs	$3.00	$3.87	-22.48%	-73.52%
May 24, 2022	-	Goldman Sachs	$4.00	$4.85	-17.53%	-64.70%

Row per page

Go to

The latest Atara Biotherapeutics stock forecast, released on Nov 13, 2024 by Benjamin Burnett from Stifel Nicolaus, set a price target of $10.00, which represents a 31.93% increase from the stock price at the time of the forecast ($7.58), and a -11.74% decrease from ATRA last price ($11.33).

Atara Biotherapeutics Price Target by Period

	1M	3M	12M
# Anlaysts	1	1	2
Avg Price Target	$10.00	$10.00	$14.00
Last Closing Price	$11.33	$11.33	$11.33
Upside/Downside	-11.74%	-11.74%	23.57%

In the current month, the average price target of Atara Biotherapeutics stock is $10.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a -11.74% decrease as opposed to Atara Biotherapeutics's last price of $11.33. This month's average price target is down 0.00% compared to last quarter, and down -28.57% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Aug 09, 2022	Goldman Sachs	Sell	Sell	Hold
May 24, 2022	Goldman Sachs	Sell	Sell	Hold

Row per page

Go to

Atara Biotherapeutics's last stock rating was published by Goldman Sachs on Aug 09, 2022. The company gave ATRA a "Sell" rating, the same as its previous rate.

Atara Biotherapeutics Financial Forecast

Atara Biotherapeutics Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Mar 15
Revenue	-	-	-	-	-	-	-	-	$4.25M	$2.14M	$957.00K	$1.23M	$221.00K	$4.46M	$51.58M	$7.31M	$7.55M	$5.37M	$3.87M	$3.55M	-	-
Avg Forecast	$8.50M	$13.10M	$11.87M	$46.90M	$17.44M	$28.66M	$37.09M	$24.69M	$2.56M	$5.09M	$4.36M	$32.01M	$34.01M	$5.13M	$6.84M	$5.79M	$31.38M	$4.55M	$4.95M	$2.05M	$15.00M	$1.05B
High Forecast	$11.83M	$18.24M	$16.52M	$76.22M	$34.61M	$39.90M	$37.09M	$24.69M	$3.02M	$7.09M	$6.07M	$44.56M	$47.34M	$5.13M	$6.84M	$5.79M	$31.38M	$4.55M	$4.95M	$2.05M	$15.00M	$1.26B
Low Forecast	$5.56M	$8.58M	$7.77M	$17.58M	$266.23K	$18.76M	$37.09M	$24.69M	$2.09M	$3.33M	$2.85M	$20.96M	$22.26M	$5.13M	$6.84M	$5.79M	$31.38M	$4.55M	$4.95M	$2.05M	$15.00M	$838.10M
# Analysts	1	1	1	2	3	1	2	2	4	2	2	2	1	1	1	1	2	2	2	2	2	13
Surprise %	-	-	-	-	-	-	-	-	1.66%	0.42%	0.22%	0.04%	0.01%	0.87%	7.54%	1.26%	0.24%	1.18%	0.78%	1.73%	-	-

Atara Biotherapeutics's average Quarter revenue forecast for Mar 24 based on 2 analysts is $24.69M, with a low forecast of $24.69M, and a high forecast of $24.69M. ATRA's average Quarter revenue forecast represents a 480.68% increase compared to the company's last Quarter revenue of $4.25M (Dec 23).

Atara Biotherapeutics EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Mar 15
# Analysts	1	1	1	2	3	1	2	2	4	2	2	2	1	1	1	1	2	2	2	2	2	13
EBITDA	-	-	-	-	-	-	-	-	$-52.07M	$-69.61M	$-71.41M	$-75.02M	$-75.54M	$-83.25M	$-80.93M	$-86.63M	$-93.40M	$-82.50M	$-81.68M	$-76.02M	$-81.70M	$-9.31M
Avg Forecast	$-1.70M	$-2.62M	$-2.37M	$-9.38M	$-3.49M	$-5.73M	$-7.42M	$-84.01M	$-512.40K	$-1.02M	$-871.80K	$-89.85M	$-60.82M	$-1.03M	$-1.37M	$-96.10M	$-6.27M	$-909.36K	$-989.35K	$-81.08M	$-3.00M	$-9.73M
High Forecast	$-1.11M	$-1.72M	$-1.55M	$-3.52M	$-53.24K	$-3.75M	$-7.42M	$-67.21M	$-418.29K	$-666.39K	$-570.72K	$-71.88M	$-48.65M	$-1.03M	$-1.37M	$-76.88M	$-6.27M	$-909.36K	$-989.35K	$-64.86M	$-3.00M	$-7.78M
Low Forecast	$-2.37M	$-3.65M	$-3.30M	$-15.24M	$-6.92M	$-7.98M	$-7.42M	$-100.81M	$-604.42K	$-1.42M	$-1.21M	$-107.82M	$-72.98M	$-1.03M	$-1.37M	$-115.32M	$-6.27M	$-909.36K	$-989.35K	$-97.29M	$-3.00M	$-11.67M
Surprise %	-	-	-	-	-	-	-	-	101.62%	68.39%	81.92%	0.83%	1.24%	81.09%	59.18%	0.90%	14.88%	90.72%	82.56%	0.94%	27.23%	0.96%

undefined analysts predict ATRA's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Atara Biotherapeutics's previous annual EBITDA (undefined) of $NaN.

Atara Biotherapeutics Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Mar 15
# Analysts	1	1	1	2	3	1	2	2	4	2	2	2	1	1	1	1	2	2	2	2	2	13
Net Income	-	-	-	-	-	-	-	-	$-60.45M	$-69.80M	$-71.11M	$-74.77M	$-74.57M	$-84.09M	$18.47M	$-87.99M	$-93.35M	$-84.66M	$-83.79M	$-78.33M	$-81.31M	$-9.16M
Avg Forecast	$-39.50M	$-29.62M	$-30.76M	$10.93M	$-29.31M	$-14.09M	$-16.71M	$-85.67M	$-83.06M	$-116.24M	$-122.48M	$-91.62M	$-62.50M	$-1.14B	$-1.22B	$-97.99M	$-1.07B	$-1.39B	$-1.34B	$-83.44M	$-1.15B	$-9.58M
High Forecast	$-21.76M	$-16.32M	$-16.95M	$230.11M	$-11.81M	$-7.77M	$-9.21M	$-68.54M	$-81.70M	$-64.05M	$-67.49M	$-73.30M	$-50.00M	$-1.14B	$-1.22B	$-78.40M	$-1.07B	$-1.39B	$-1.34B	$-66.76M	$-1.15B	$-7.66M
Low Forecast	$-59.63M	$-44.72M	$-46.44M	$-208.26M	$-46.76M	$-21.28M	$-25.23M	$-102.80M	$-84.42M	$-175.51M	$-184.92M	$-109.95M	$-75.00M	$-1.14B	$-1.22B	$-117.59M	$-1.07B	$-1.39B	$-1.34B	$-100.13M	$-1.15B	$-11.49M
Surprise %	-	-	-	-	-	-	-	-	0.73%	0.60%	0.58%	0.82%	1.19%	0.07%	-0.02%	0.90%	0.09%	0.06%	0.06%	0.94%	0.07%	0.96%

Atara Biotherapeutics's average Quarter net income forecast for Sep 22 is $-1.14B, with a range of $-1.14B to $-1.14B. ATRA's average Quarter net income forecast represents a -6300.30% decrease compared to the company's last Quarter net income of $18.47M (Jun 22).

Atara Biotherapeutics SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Mar 15
# Analysts	1	1	1	2	3	1	2	2	4	2	2	2	1	1	1	1	2	2	2	2	2	13
SG&A	-	-	-	-	-	-	-	-	$10.39M	$12.25M	$13.34M	$13.87M	$13.24M	$18.92M	$18.81M	$20.57M	$21.82M	$19.85M	$19.40M	$17.74M	$16.14M	$3.54M
Avg Forecast	$21.77M	$33.56M	$30.40M	$120.14M	$44.67M	$73.42M	$95.02M	$20.00M	$6.56M	$13.04M	$11.17M	$21.39M	$14.61M	$13.15M	$17.52M	$14.83M	$80.37M	$11.65M	$12.67M	$5.26M	$38.42M	$3.71M
High Forecast	$30.31M	$46.72M	$42.32M	$195.25M	$88.66M	$102.21M	$95.02M	$24.00M	$7.74M	$18.15M	$15.55M	$25.67M	$17.53M	$13.15M	$17.52M	$14.83M	$80.37M	$11.65M	$12.67M	$5.26M	$38.42M	$4.45M
Low Forecast	$14.25M	$21.97M	$19.90M	$45.03M	$681.99K	$48.06M	$95.02M	$16.00M	$5.36M	$8.54M	$7.31M	$17.11M	$11.69M	$13.15M	$17.52M	$14.83M	$80.37M	$11.65M	$12.67M	$5.26M	$38.42M	$2.96M
Surprise %	-	-	-	-	-	-	-	-	1.58%	0.94%	1.19%	0.65%	0.91%	1.44%	1.07%	1.39%	0.27%	1.70%	1.53%	3.37%	0.42%	0.96%

Atara Biotherapeutics's average Quarter SG&A projection for Mar 24 is $20.00M, based on 2 Wall Street analysts, with a range of $16.00M to $24.00M. The forecast indicates a 92.55% rise compared to ATRA last annual SG&A of $10.39M (Dec 23).

Atara Biotherapeutics EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Mar 15
# Analysts	1	1	1	2	3	1	2	2	4	2	2	2	1	1	1	1	2	2	2	2	2	13
EPS	-	-	-	-	-	-	-	-	$-0.56	$-0.66	$-0.68	$-0.72	$-0.72	$-0.82	$0.18	$-0.87	$-0.96	$-0.90	$-0.91	$-0.86	$-0.95	$-0.42
Avg Forecast	$-5.29	$-3.97	$-4.12	$1.46	$-3.93	$-1.89	$-2.24	$-6.42	$-11.13	$-15.57	$-16.40	$-9.27	$-12.99	$-18.64	$-19.90	$-23.30	$-17.35	$-22.55	$-21.82	$-22.53	$-18.66	$-0.46
High Forecast	$-2.92	$-2.19	$-2.27	$30.82	$-1.58	$-1.04	$-1.23	$-3.54	$-10.94	$-8.58	$-9.04	$-5.11	$-7.16	$-18.64	$-19.90	$-23.30	$-17.35	$-22.55	$-21.82	$-22.53	$-18.66	$-0.37
Low Forecast	$-7.99	$-5.99	$-6.22	$-27.89	$-6.26	$-2.85	$-3.38	$-9.69	$-11.31	$-23.51	$-24.77	$-13.99	$-19.62	$-18.64	$-19.90	$-23.30	$-17.35	$-22.55	$-21.82	$-22.53	$-18.66	$-0.55
Surprise %	-	-	-	-	-	-	-	-	0.05%	0.04%	0.04%	0.08%	0.06%	0.04%	-0.01%	0.04%	0.06%	0.04%	0.04%	0.04%	0.05%	0.91%

According to 1 Wall Street analysts, Atara Biotherapeutics's projected average Quarter EPS for Sep 22 is $-18.64, with a low estimate of $-18.64 and a high estimate of $-18.64. This represents a -10454.58% decrease compared to ATRA previous annual EPS of $0.18 (Jun 22).

Atara Biotherapeutics Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
BTAI	BioXcel Therapeutics	$0.58	$12.00	1968.97%	Buy
FATE	Fate Therapeutics	$2.27	$39.67	1647.58%	Buy
ALLO	Allogene Therapeutics	$2.15	$29.00	1248.84%	Buy
XFOR	X4 Pharmaceuticals	$0.37	$3.67	891.89%	Buy
KPTI	Karyopharm Therapeutics	$0.79	$7.33	827.85%	Buy
HRTX	Heron Therapeutics	$1.17	$7.00	498.29%	Buy
ITOS	iTeos Therapeutics	$7.88	$37.67	378.05%	Buy
SANA	Sana Bio	$2.34	$8.00	241.88%	Buy
ABOS	Acumen Pharmaceuticals	$2.24	$7.00	212.50%	Buy
TCRX	TScan Therapeutics	$4.20	$12.00	185.71%	Buy
APLS	Apellis Pharmaceuticals	$26.18	$74.50	184.57%	Buy
RCUS	Arcus Biosciences	$14.43	$33.00	128.69%	Buy
MREO	Mereo BioPharma Group	$3.33	$6.75	102.70%	Buy
CRBU	Caribou Biosciences	$1.98	$3.00	51.52%	Buy
HOOK	HOOKIPA Pharma	$2.80	$3.00	7.14%	Buy
VECT	VectivBio	$16.87	$18.00	6.70%	Buy
ATRA	Atara Biotherapeutics	$11.33	$10.33	-8.83%	Sell

ATRA Forecast FAQ

Is Atara Biotherapeutics a good buy?

No, according to 1 Wall Street analysts, Atara Biotherapeutics (ATRA) is considered a 'Sell'. The rating consensus is based on 0 'Strong Buy' and 0 'Buy' recommendations, accounting for 0% of ATRA's total ratings.

What is ATRA's price target?

Atara Biotherapeutics (ATRA) average price target is $10.33 with a range of $3 to $18, implying a -8.83% from its last price of $11.33. The data is based on 1 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Atara Biotherapeutics stock go up soon?

According to Wall Street analysts' prediction for ATRA stock, the company can go down by -8.83% (from the last price of $11.33 to the average price target of $10.33), up by 58.87% based on the highest stock price target, and down by -73.52% based on the lowest stock price target.

Can Atara Biotherapeutics stock reach $20?

ATRA's average twelve months analyst stock price target of $10.33 does not support the claim that Atara Biotherapeutics can reach $20 in the near future.

What is Atara Biotherapeutics's current price target trend?

1 Wall Street analyst forecast a $10 price target for Atara Biotherapeutics (ATRA) this month, down -11.74% from its last price of $11.33. Compared to the last 3 and 12 months, the average price target decreased by -11.74% and increased by 23.57%, respectively.

What are Atara Biotherapeutics's analysts' financial forecasts?

Atara Biotherapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $107.88M (high $136.29M, low $80.81M), average EBITDA is $-101M (high $-78.432M, low $-123M), average net income is $-146M (high $-97.319M, low $-196M), average SG&A $233.11M (high $309.89M, low $159.76M), and average EPS is $-14.468 (high $-7.391, low $-22.18). ATRA's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $80.37M (high $122.81M, low $39.49M), average EBITDA is $-16.073M (high $-7.898M, low $-24.563M), average net income is $-88.945M (high $175.08M, low $-359M), average SG&A $205.87M (high $314.61M, low $101.16M), and average EPS is $-11.913 (high $23.45, low $-48.092).

Did the ATRA's actual financial results beat the analysts' financial forecasts?

Based on Atara Biotherapeutics's last annual report (Dec 2023), the company's revenue was $8.57M, which missed the average analysts forecast of $44.02M by -80.52%. Apple's EBITDA was $-276M, beating the average prediction of $-92.253M by 199.18%. The company's net income was $-276M, missing the average estimation of $-413M by -33.21%. Apple's SG&A was $50.91M, missing the average forecast of $52.16M by -2.40%. Lastly, the company's EPS was $-2.61, missing the average prediction of $-52.364 by -95.02%. In terms of the last quarterly report (Dec 2023), Atara Biotherapeutics's revenue was $4.25M, beating the average analysts' forecast of $2.56M by 65.96%. The company's EBITDA was $-52.072M, beating the average prediction of $-512K by 10062.39%. Atara Biotherapeutics's net income was $-60.45M, missing the average estimation of $-83.059M by -27.22%. The company's SG&A was $10.39M, beating the average forecast of $6.56M by 58.28%. Lastly, the company's EPS was $-0.56, missing the average prediction of $-11.125 by -94.97%